WellCare biologics denied: how to appeal

Quick answer

If WellCare (Centene) denied your biologic and infusion therapy, you can appeal, and the plan must give you its file and the criteria it used. Filing windows by plan type: 65 days from the notice (Medicare Advantage); 65 days from the notice (Part D). The date printed on your denial notice controls; it can only be later than these floors, never earlier.

Why WellCare (Centene) denies biologic and infusion therapy

WellCare is Centene's Medicare Advantage and Part D brand, with a large footprint in MA-PD and standalone Part D plans. Because WellCare operates under Medicare, appeals follow the federal 5-level Medicare Advantage and Part D appeal ladders rather than state external-review programs.

For biologic and infusion therapy specifically: Biologics such as adalimumab, infliximab, vedolizumab, ustekinumab, and rituximab are denied at prior authorization for step-therapy, missing labs, or diagnosis mismatch, and later for site of care or dose escalation. The appeal is a documentation exercise against the plan's own criteria.

The law that controls this appeal

Plan drug policies typically require a specific diagnosis, disease severity measures, a trial of conventional therapy (step therapy), tuberculosis and hepatitis screening, and prescriber specialty. Many states limit step therapy and require exception processes; federal rules for ACA plans require an exceptions process for non-formulary drugs (45 CFR 156.122(c)). Medicare Part B covers physician-administered biologics under medical necessity; Part D covers self-administered ones under formulary rules with a 60-day redetermination window (42 CFR 423.582). Criteria must be disclosed on request.

Note for WellCare (Centene): where the standard above cites ERISA or the ACA appeal rules, those describe employer and Marketplace plans. The windows and levels that apply to WellCare (Centene) are in the table below.

At a glance

WellCare (Centene) appeals: the rule, the deadline and the next level, by plan type

Which row applies depends on the plan you hold, not on WellCare (Centene)'s brand. Your ID card, the Summary Plan Description and the denial letter say which.

Plan type	Rule that governs	File your appeal within	The plan must answer	If the plan says no again
Medicare Advantage (Part C) A private plan that replaces Original Medicare. The card says Medicare Advantage, HMO, PPO or PFFS.	42 CFR Part 422, Subpart M (§§ 422.560 to 422.634). Coverage decisions must follow Original Medicare rules (42 CFR 422.101).	65 calendar days from the date on the denial notice to request the plan's reconsideration (42 CFR 422.582, as amended effective 1 January 2025).	Expedited: 72 hours. Standard pre-service: 30 days (7 days for Part B drugs). Payment: 60 days (42 CFR 422.590).	If the plan does not fully reverse itself it must send the case to the Independent Review Entity on its own (42 CFR 422.592); then an ALJ hearing when the amount in controversy meets the annual threshold, the Medicare Appeals Council and federal court. State external review does not apply.
Medicare Part D (drug plan or MA-PD) A stand-alone drug plan or the drug benefit inside a Medicare Advantage plan.	42 CFR Part 423, Subpart M; exceptions under 42 CFR 423.578.	65 calendar days from the date on the notice to request a redetermination (42 CFR 423.582, as amended effective 1 January 2025). Formulary, tiering and step-therapy exceptions need the prescriber's supporting statement (§ 423.578).	Redetermination: 7 calendar days standard, 72 hours expedited (42 CFR 423.590). Coverage determinations: 72 hours standard, 24 hours expedited, once the prescriber's statement is received (§§ 423.568, 423.572).	Independent Review Entity reconsideration on your request within 65 days of the redetermination notice (§ 423.600); then ALJ, Council and court.

Medicare Advantage (Part C)

What you can demand. The plan may not apply internal criteria that are more restrictive than Medicare's national and local coverage determinations, and must decide medical necessity on your individual circumstances (42 CFR 422.101(b), (c)). You can ask for the case file and the criteria used.

How to open the appeal. Cite 42 CFR 422.582 and 422.101(c): the plan must decide on your individual circumstances under Medicare coverage rules, and must forward an unfavorable reconsideration to the IRE itself.

Medicare Part D (drug plan or MA-PD)

What you can demand. The exception turns on the prescriber's statement that the formulary alternative would be less effective or would harm you (42 CFR 423.578(b)(5)).

How to open the appeal. Cite 42 CFR 423.578 and 423.582 and attach the prescriber's supporting statement written to the exception standard.

Primary sources for this table

Windows are federal floors or the rule as written; the denial notice controls. Reviewed 13 September 2026. General information, not legal advice; Apellica is not a law firm.

What WellCare (Centene) denies for biologic and infusion therapy

The biologic and infusion therapy services most often denied:

First biologic for Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, or psoriasis
Switch to a second biologic after the first stops working
Dose escalation or interval shortening beyond the label
Infusion at a hospital outpatient department instead of home or a standalone center
Biosimilar substitution disputes

Why biologic and infusion therapy claims get denied

A typical WellCare (Centene) biologic and infusion therapy denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:

Step therapy: conventional drugs (methotrexate, mesalamine, steroids) not tried or not documented
Disease activity scores or lab markers missing from the record
Diagnosis code does not match the labeled indication
TB or hepatitis B screening not on file
Plan prefers a different biologic or a biosimilar first

The WellCare (Centene) appeal process

Appeal levels: Federal Medicare 5-level ladder: plan reconsideration → IRE (MAXIMUS) → ALJ → Medicare Appeals Council → federal district court. Fast-track QIO review for inpatient and post-acute terminations.

Carrier timing: 65 days from the notice for plan reconsideration and Part D redetermination (42 CFR 422.582, 423.582); 60 days for later levels. Expedited urgent decisions in 72 hours. The ALJ level requires the amount in controversy to meet the annual threshold CMS publishes.

Biologics timing for WellCare (Centene): the filing windows and decision clocks in the table above apply; the date on the notice controls.

What we know about WellCare (Centene): WellCare cases benefit from early escalation. We do not stop at the plan-level denial, the IRE and ALJ levels are where complex reversals happen.

Common WellCare (Centene) denial patterns for biologic and infusion therapy

Plan reconsideration is just the first step. WellCare's plan-level reconsideration is level 1. A meaningful share of denials reverse only at level 2 (MAXIMUS IRE) or higher. Members who stop at the plan denial often leave a winnable case on the table.
Part D formulary and tiering exceptions. WellCare Part D denials route through coverage determination → redetermination → IRE → ALJ. Formulary exception requests with prescriber clinical support are the standard entry point for non-formulary drugs.
Skilled nursing and home health terminations. WellCare MA plans, like other MA carriers, have been subject to CMS scrutiny on early termination of post-acute care. Expedited fast-track appeals through the Beneficiary and Family Centered Care QIO are available when termination notices are issued.

How to win your WellCare (Centene) biologic and infusion therapy appeal

Strategy for biologic and infusion therapy: Get the plan's drug policy and match every criterion to a page in the chart: diagnosis, severity score, prior drugs with dates and outcomes, screening labs, prescriber specialty. Where step therapy is the reason, use the plan's exception process and, where applicable, the state step-therapy law that requires an override when the required drug was tried, is contraindicated, or is expected to be ineffective. For a switch after loss of response, document the objective loss of response. Ask for a peer-to-peer with a reviewer in the same specialty.

Filed against WellCare (Centene), that strategy rides on this procedural spine:

Procedural-rights anchor. Cite 42 CFR 422.582 and 422.101(c): the plan must decide on your individual circumstances under Medicare coverage rules, and must forward an unfavorable reconsideration to the IRE itself. If your WellCare (Centene) coverage is a different plan type (Medicare Part D), use that row of the table above instead; the rule and the deadline change with the plan, not the carrier.
Criteria-disclosure demand. WellCare (Centene) frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
Controlling-standard citation. Plan drug policies typically require a specific diagnosis, disease severity measures, a trial of conventional therapy (step therapy), tuberculosis and hepatitis screening, and prescriber specialty. Many states limit step therapy and require exception processes; federal rules for ACA plans require an exceptions process for non-formulary drugs (45 CFR 156.122(c)). Medicare Part B covers physician-administered biologics under medical necessity; Part D covers self-administered ones under formulary rules with a 60-day redetermination window (42 CFR 423.582). Criteria must be disclosed on request.
Treating-provider attestation. A letter from the treating physician addressing each criterion in WellCare (Centene)'s own policy language. This is the single strongest evidentiary element.
Requested action. A specific demand to reverse the biologic and infusion therapy denial and approve the service, not a general "please reconsider."

Documents you'll need for your WellCare (Centene) biologic and infusion therapy appeal

The denial letter with the criterion or policy cited
Specialist's notes with diagnosis and disease-activity measures
Prior medication history with dates, doses, and outcomes
TB, hepatitis, and other screening results
The plan's drug policy and formulary exception form

What a biologic and infusion therapy appeal can recover

Typical recovery for biologic and infusion therapy cases runs Biologics are priced in the thousands of dollars per dose; a denied year of therapy is commonly a five-figure sum at billed charges.. The exact figure depends on the specific service and your plan's contracted rates.

WellCare (Centene) biologic and infusion therapy appeals: frequently asked questions

WellCare (Centene) wants me to fail a cheaper drug first. Do I have to?

Not always. Plans must have an exception process, and many states require an override when the required drug was already tried, is contraindicated, or is expected to be ineffective. The prescriber's letter should say which of those applies and why.

Why was my biologic denied when my doctor prescribed it?

Most denials are documentation gaps: a missing severity score, an undocumented prior drug, or a screening lab not on file. The plan's policy tells you exactly which item is missing; request it.

WellCare (Centene) moved my infusions out of the hospital. Can I appeal the site of care?

Yes. Site-of-care denials are appealable. The record needs to show why the hospital setting is medically required, for example prior infusion reactions or complex comorbidities.

Is a biosimilar the same drug?

A biosimilar is highly similar to the reference biologic with no clinically meaningful difference, per FDA. Plans may prefer one. If a switch caused loss of response or an adverse reaction, that history is the basis for an exception.

What Apellica does for WellCare (Centene) biologic and infusion therapy appeals

We file appeals against WellCare (Centene) specifically configured to its internal review process. Every biologic and infusion therapy appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.

Cost: $0 upfront. We work on contingency for WellCare (Centene) appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.

Start your WellCare (Centene) biologic and infusion therapy appeal

Submit a 2-minute intake. A senior reviewer responds within one business day with the specific appeal strategy for your case.

Start free appeal review →

WellCare (Centene) denied your biologic and infusion therapy? Here is what to do next